Maxine L. Stitzer

19.6k total citations · 2 hit papers
334 papers, 14.5k citations indexed

About

Maxine L. Stitzer is a scholar working on Epidemiology, Public Health, Environmental and Occupational Health and Physiology. According to data from OpenAlex, Maxine L. Stitzer has authored 334 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Epidemiology, 126 papers in Public Health, Environmental and Occupational Health and 89 papers in Physiology. Recurrent topics in Maxine L. Stitzer's work include Substance Abuse Treatment and Outcomes (124 papers), Opioid Use Disorder Treatment (102 papers) and Smoking Behavior and Cessation (74 papers). Maxine L. Stitzer is often cited by papers focused on Substance Abuse Treatment and Outcomes (124 papers), Opioid Use Disorder Treatment (102 papers) and Smoking Behavior and Cessation (74 papers). Maxine L. Stitzer collaborates with scholars based in United States, United Kingdom and Bulgaria. Maxine L. Stitzer's co-authors include George E. Bigelow, Ira A. Liebson, Eric C. Strain, Sharon Walsh, Mary Ann Chutuape, Kenneth Silverman, Kenzie L. Preston, Rolley E. Johnson, George E. Bigelow and Stephen J. Heishman and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Maxine L. Stitzer

331 papers receiving 13.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical pharmacology of buprenorphine: Ceiling effects at high doses

1994 618 citations Sharon Walsh, Kenzie L. Preston et al. profile →
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence

2000 507 citations Mary Ann Chutuape, Eric C. Strain et al. profile →

Peers

Countries citing papers authored by Maxine L. Stitzer

Since Specialization

Citations

This map shows the geographic impact of Maxine L. Stitzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maxine L. Stitzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maxine L. Stitzer more than expected).

Fields of papers citing papers by Maxine L. Stitzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maxine L. Stitzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maxine L. Stitzer. The network helps show where Maxine L. Stitzer may publish in the future.

Co-authorship network of co-authors of Maxine L. Stitzer

This figure shows the co-authorship network connecting the top 25 collaborators of Maxine L. Stitzer. A scholar is included among the top collaborators of Maxine L. Stitzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maxine L. Stitzer. Maxine L. Stitzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tobacco use behaviors and views on engaging in clinical trials for tobacco cessation among individuals who experience homelessness 2023 ·Contemporary Clinical Trials Communications ·Joshua D. Miller, (unknown), Sharon M. Hall, Maxine L. Stitzer, Margot Kushel, (unknown), Maya Vijayaraghavan	2
2	Evaluation of real‐world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders 2022 ·American Journal on Addictions ·Xiaorui Xiong, (unknown), Maxine L. Stitzer, Hilary F. Luderer, (unknown), Brendan Hare, Michael R. Stevenson, (unknown)	10
3	Contingency management to promote smoking cessation in people experiencing homelessness: Leveraging the electronic health record in a pilot, pragmatic randomized controlled trial 2022 ·PLoS ONE ·Melanie F. Molina, Sharon M. Hall, Maxine L. Stitzer, Margot Kushel, Deepalika Chakravarty, Maya Vijayaraghavan	4
4	Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid use disorder and other vulnerabilities. 2020 ·Experimental and Clinical Psychopharmacology ·(unknown), (unknown), Jeffrey S. Priest, Cecilia L. Bergeria, Danielle R. Davis, John R. Hughes, Andrea C. Villanti, Jennifer W. Tidey, (unknown), (unknown), Maxine L. Stitzer, Stephen T. Higgins	8
5	Enhancing Patient Navigation with Contingent Incentives to Improve Healthcare Behaviors and Viral Load Suppression of Persons with HIV and Substance Use 2018 ·AIDS Patient Care and STDs ·Maxine L. Stitzer, Alexis S. Hammond, Tim Matheson, James L. Sorensen, Daniel J. Feaster, Rui Duan, Lauren Gooden, Carlos del Rı́o, Lisa R. Metsch	12
6	Contingency Management: New Directions and Remaining Challenges for An Evidence-Based Intervention 2016 ·Journal of Substance Abuse Treatment ·Carla J. Rash, Maxine L. Stitzer, Jeremiah Weinstock	42
7	A Comparison of Reinforcement Based Treatment (RBT) versus RBT plus Recovery Housing (RBTRH) 2016 ·Journal of Substance Abuse Treatment ·Michelle Tuten, Julia M. Shadur, Maxine L. Stitzer, Hendrée E. Jones	14
8	Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring 2015 ·Journal of Substance Abuse Treatment ·(unknown), Maxine L. Stitzer, Aimee Campbell, Martina Pavlicová, (unknown), Edward V. Nunes	13
9	Cognitive impairment in methadone maintenance patients 2002 ·Drug and Alcohol Dependence ·Miriam Z. Mintzer, Maxine L. Stitzer	210
10	Methadone treatment for opioid dependence 1999 ·Johns Hopkins University Press eBooks ·Eric C. Strain, Maxine L. Stitzer	46
11	Survey Assessment of Methadone Treatment Services as Reinforcers 1998 ·The American Journal of Drug and Alcohol Abuse ·Mary Ann Chutuape, Kenneth Silverman, Maxine L. Stitzer	39
12	Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Kory Schuh, Sharon Walsh, George E. Bigelow, Kenzie L. Preston, Maxine L. Stitzer	37
13	Comparative clinical pharmacology of short-acting mu opioids in drug abusers. 1996 ·Journal of Pharmacology and Experimental Therapeutics ·Mark K. Greenwald, Harry L. June, Maxine L. Stitzer, Alan P. Marco	24
14	Buprenorphine Versus Methadone in the Treatment of Opioid Dependence 1996 ·Journal of Clinical Psychopharmacology ·Eric C. Strain, Maxine L. Stitzer, Ira A. Liebson, George E. Bigelow	113
15	Clinical pharmacology of buprenorphine 1995 ·Maxine L. Stitzer, Sharon Walsh, Eric C. Strain, Kory Schuh, G. E. Bigelow, Walter Ling, C. James Klett, Margaret A. Compton	8
16	Dose effects of nicotine gum 1995 ·Addictive Behaviors ·Janet Gross, Jeffrey P. Johnson, (unknown), Maxine L. Stitzer	26
17	Effects of buprenorphine and methadone in methadone-maintained subjects 1995 ·Psychopharmacology ·Sharon Walsh, Harry L. June, Kory Schuh, Kenzie L. Preston, George E. Bigelow, Maxine L. Stitzer	103
18	Treatment issues: towards a stepped-care model 1993 ·Tobacco Control ·(unknown), David B. Abrams, Maxine L. Stitzer, Raymond Niaura, M GOLDSTEIN, Wayne F. Velicer, James O. Prochaska, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	39
19	Experimental model of smoking re-exposure: effects on relapse 1992 ·Psychopharmacology ·(unknown), Maxine L. Stitzer, Janet Gross, Scott J. Leischow	67
20	Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I. 1989 ·Journal of Pharmacology and Experimental Therapeutics ·Stephen J. Heishman, Maxine L. Stitzer, George E. Bigelow, Ira A. Liebson	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact